Efficacy and Safety of Sitagliptin in the Treatment of COVID-19

被引:6
作者
Mikhael, Ehab Mudher [1 ,2 ]
Ong, Siew Chin [1 ]
Sheikh Ghadzi, Siti Maisharah [1 ]
机构
[1] Univ Sains Malaysia, Sch Pharmaceut Sci, Gelugor 11800, Penang, Malaysia
[2] Univ Baghdad, Clin Pharm Dept, Coll Pharm, Baghdad, Iraq
关键词
Sitagliptin; COVID-19; METAANALYSIS; INHIBITORS;
D O I
10.1177/08971900221102119
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality especially among diabetes mellitus (DM) patients. Effective treatments against COVID-19 can complement the vaccination effort worldwide. Many review articles studied the effects of the dipeptidyl peptidase 4 (DPP-4) inhibitors among COVID-19 patients and found conflicting results. This heterogeneity may be due to different systemic pleiotropic effects of different DPP-4 inhibitors. Sitagliptin appears to be one of the good DPP-4 inhibitors that have antiinflammatory and antithrombotic effect. Therefore, this review assessed the benefits and safety of sitagliptin in the treatment of COVID-19. Methods: A detailed literature review using the electronic databases of Pubmed and Google Scholar was conducted during July and August 2021 to find out studies that published in English language and discussed the role of sitagliptin for COVID-19 patients. Results: 14 articles were eligible and thus included in this narrative review. Nine of these articles agreed to the benefit of sitagliptin in the treatment of COVID-19, while 3 studies considered sitagliptin as non useful or even risky, and one study was neutral in its conclusion towards the usage of sitagliptin in COVID-19. Only one study focused on the safety of sitagliptin and found that it is safe. Conclusion: Sitagliptin has anti-inflammatory, antifibrotic and antiapoptotic properties; such effects may be beneficial in reducing risks of COVID-19. Sitagliptin has good safety and fair benefits to reduce mortality among DM patients with COVID-19. Further randomized clinical trials are needed to confirm these benefits especially among patients without DM.
引用
收藏
页码:980 / 987
页数:8
相关论文
共 50 条
  • [31] Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19
    Meo, S. A.
    Klonoff, D. C.
    Akram, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (08) : 4539 - 4547
  • [32] Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
    Bai, Yuan
    Shen, Mingwang
    Zhang, Lei
    VIRUSES-BASEL, 2022, 14 (04):
  • [33] Efficacy and Safety of Inhalation of Nebulized Ethanol in COVID-19 Treatment: A Randomized Clinical Trial
    Amoushahi, Ali
    Moazam, Elham
    Tabatabaei, Amin Reza
    Ghasimi, Golnaz
    Grant-Whyte, Ian
    Salvatori, Pietro
    Ezz, Ahmed Ragab
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [34] Evaluation of the safety and efficacy of isotretinoin in treatment of COVID-19: A randomized controlled clinical trial
    Elgarhy, Lamia H.
    El-Ghaiesh, Sabah H.
    Hamed, Eman
    Abdelfatah, Wagdy
    CONTEMPORARY CLINICAL TRIALS, 2025, 150
  • [35] Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19
    Papi, Alberto
    Stapleton, Renee D.
    Shore, Paul M.
    Bica, Mihai Alexandru
    Chen, Younan
    Larbig, Michael
    Welte, Tobias
    LUNG, 2023, 201 (02) : 159 - 170
  • [36] Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19
    Wei, Fengtao
    Kong, Dexiao
    Li, Tao
    Li, Ai
    Tan, Yi
    Fang, Jinfeng
    Zhuang, Xianghua
    Lai, Chao
    Xu, Weihua
    Dong, Hong
    Ma, Chengen
    Hong, Ke
    Cui, Yuqin
    Tang, Shengbin
    Yu, Fenggang
    Zheng, Chengyun
    CLINICS, 2021, 76
  • [37] Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19
    Alberto Papi
    Renee D. Stapleton
    Paul M. Shore
    Mihai Alexandru Bica
    Younan Chen
    Michael Larbig
    Tobias Welte
    Lung, 2023, 201 : 159 - 170
  • [38] Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens
    Karatza, Eleni
    Ismailos, George
    Karalis, Vangelis
    XENOBIOTICA, 2021, 51 (06) : 643 - 656
  • [39] Diabetes and COVID-19
    Bouhanick, Beatrice
    Cracowski, Jean-Luc
    Faillie, Jean-Luc
    THERAPIE, 2020, 75 (04): : 327 - 333
  • [40] Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis
    Jiang, Weijun
    Li, Weiwei
    Wu, Qiuyue
    Han, Ying
    Zhang, Jing
    Luo, Tao
    Guo, Yanju
    Yang, Yang
    Zhu, Peiran
    Xia, Xinyi
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (03) : 1677 - 1698